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Abstract
Background: The use of tocolytics is central in delaying birth; however, therapeutic options vary in
effectiveness and adverse events profiles, which in turn could have consequences for medical resource use
and cost of treatment.
Betamimetics are commonly used tocolytic agents, but their mechanism of action affects multiple organ
systems leading to numerous adverse events. The availability of an oxytocin receptor antagonist, specific
for prevention of preterm labour, offers a treatment option that merits further evaluation. We aimed to
compare economic implications of tocolysis using atosiban and betamimetics, considering treatment
efficacy and safety, as well as cost consequences of treatment of associated adverse events.
Methods: A systematic literature review identified six randomised clinical trials, three of them double-
blinded, comparing atosiban with betamimetics, in which tocolysis was initiated within 48 hours of
admission. Cost of drug treatment was calculated based on trial protocols and German hospital drug
purchase costs. G-DRG Grouper was used to obtain cost per case. The drug regimen was concordant
with the German guidelines for the management of preterm labour, with two alternative modalities of
fenoterol analysed: continuous or bolus administrations.
Results: According to the results of the meta-analysis of the three double-blinded, placebo-controlled
clinical trials, atosiban and betamimetics have similar efficacy (RR = 0.99, 95%CI:0.94–1.04, p = 0.772).
Compared to betamimetics, use of atosiban was associated with a significantly lower frequency of adverse
events for tachycardia, palpitation, vomiting, headache, hyperglycaemia, tremor, dyspnoea, chest pain,
hypocalemia and foetal tachycardia.
In our economic analysis, cost savings from using atosiban versus continuous, or bolus, fenoterol was 423€
per patient from the payer's perspective. From the hospital's perspective, savings from using atosiban
versus continuous fenoterol ranged from 259€ for 18 hours of tocolysis to 105€ for 48 hours; the
respective values for bolus fenoterol were 244€ and 55€. In the probabilistic sensitivity analysis atosiban
was cost saving versus both continuous and bolus fenoterol in 87%–100% of scenarios.
Conclusion: In a German setting, atosiban is cost saving versus betamimetics in the treatment of preterm
labour from the payer, hospital and combined perspectives. Cost savings stem from the superior safety
profile of atosiban.
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Background
Preterm birth, defined as birth prior to completion of 37
weeks of gestation [1], occurs in 5–12% of all pregnancies
in industrialised countries [2,3]. In addition to the enor-
mous negative psychosocial and emotional burden on the
family, preterm birth is associated with significant cost
implications for society. In the USA alone annual cost of
$26.2 billion or $51,600 per infant, has been attributed to
preterm birth [4].
Despite intensive worldwide efforts to reduce the preterm
birth rate, over the last 10 years it has risen in Germany to
9% of all pregnancies [5]. This reflects a 20% increase over
the same period. Similarly, in the USA there has been a
noticeable 38% increase in preterm deliveries since 1981
to reach 12.7% of all pregnancies [5].
Preterm birth accounts for 75% of all causes of perinatal
mortality and the total risk for childhood disabilities is
10–15% for births before the 37th  week of gestation.
Moreover, sixty five percent of children born before the
26th week of gestation will not survive, and only 13% will
survive for 30 months without a handicap [6,7].
The onset of preterm labour is believed to be a syndrome
initiated by multiple mechanisms, including intrauterine
infection or inflammation, uteroplacental ischemia or
haemorrhage, uterine over-distension, stress, or other
immunologically mediated processes [4]. Due to the mul-
tifactorial origin, treatment options generally target the
inhibition of uterine contractility, rather than the under-
lying mechanisms of preterm labour.
Tocolytics, used in Europe for the last 30 years, are the
backbone of treatment for the prevention of preterm
labour. Tocolytic drugs are indicated to prolong preg-
nancy in women with acute risk of preterm birth; in some
cases, they are also administered for prophylaxis. The
main rationale for use of these drugs is to delay delivery
for at least 48 hours in order to allow time for the treat-
ment effect of corticosteroids, or transfer of the pregnant
mother to a specialized high-risk obstetrical unit [8]. Both
actions have been shown to markedly reduce neonatal
morbidity and/or mortality.
As most randomized trials (RCTs) of tocolytic agents lack
power to provide definitive answers, and use delay in
delivery as a surrogate endpoint for implied improve-
ments in neonatal outcome related to the administration
of steroids, systematic reviews and meta-analyses have
been conducted to more adequately study drug efficacy
and safety. Several Cochrane reviews have been published
that compared different tocolytic agents to each other or
to placebo for women in preterm labour [9-14]. Of these
medications, cyclo-oxygenase (COX) inhibitors were con-
sidered to have an inadequate knowledge base to be rec-
ommended for use [9]. Magnesium sulphate was
demonstrated to be an ineffective tocolytic agent, with an
increased risk of infant mortality [10]. Prophylactic oral
betamimetics for preventing preterm birth in women at
high risk of preterm labour with a singleton pregnancy
were inadequately studied to provide any definitive
answers [11], but betamimetics in general have been
shown to delay delivery [12]. Even so, multiple adverse
events must be considered prior to its explicit recommen-
dation. Nifedipine was shown to be preferable to other
tocolytic agents regarding maternal and neonatal out-
comes, but no placebo-controlled trials were available to
reviewers [13]. Finally, atosiban was considered to be
equivalent to betamimetics in preventing preterm labour
[14].
The choice of tocolytic agent depends mainly on the avail-
ability following regulatory approval in the country, the
drug efficacy and effectiveness, the foetal and maternal
safety profiles, and the costs of treatment. In Germany,
only atosiban, fenoterol, and magnesium sulphate (in
limited situations) are approved for treatment of preterm
labour [15].
Betamimetics are commonly used in tocolysis, but since
their mechanism of action is organ non-specific, they
notoriously lead to numerous adverse events in multiple
organ systems, which are largely of cardiovascular origin.
With similar efficacy, the benefits of atosiban result from
the significantly better safety profile with a significantly
lower rate of foetal and maternal side effects and a signif-
icantly lower rate of treatment discontinuation [16].
Many centres use nifedipine, a calcium channel blocker,
as a relatively inexpensive, orally administered tocolytic.
In the Cochrane review comparing calcium channel
blockers to other tocolytic agents, mainly betamimetics,
the former was shown to be an effective treatment option
[13]. Even so, due to the lack of regulatory approval in
Germany, and most other countries, nifedipine is only
being used off-label for the treatment of preterm labour.
A recent study by Hayes et al. [17] reported the probability
of adverse events (AEs) for various tocolytic treatments
and the costs attributed to AEs in the United States.
Because treatment practices and reimbursement mecha-
nisms in preterm labour differ between Europe and the
US, we undertook an economic evaluation of tocolytic
therapy for the treatment of preterm labour comparing
atosiban with betamimetics using a study design similar
to Hayes et al., but incorporating the German cost data in
a system of payer-provider split.
Methods
We systematically searched MEDLINE, EMBASE, the Cen-
tre for Reviews and Dissemination (CRD) and theBMC Pregnancy and Childbirth 2009, 9:23 http://www.biomedcentral.com/1471-2393/9/23
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Cochrane Central Register of Controlled Trials (CEN-
TRAL) databases to identify randomized clinical trials
comparing atosiban versus betamimetics in women expe-
riencing preterm labour. No search restrictions were
applied and all abstracts identified using the keywords
"atosiban", "Tractocile", "antocin", and/or "RWJ 22164"
were considered. For the meta-analysis of efficacy and
rates of adverse events, we included trials that provided
outcomes during 48 hours of hospitalisation. Three types
of outcomes data were extracted from the selected studies:
efficacy in delaying preterm birth by at least 48 hours, fre-
quency of maternal and foetal adverse events, and
resource utilisation for the economic analysis. The inclu-
sion criteria in the identified three double-blinded studies
were: regular preterm uterine contractions, cervical dilata-
tion of 0–3 cm (for nulliparae) or 1–3 cm (for multi-
parae), cervical effacement of ≥50%, ≥18 years of age or of
legal consenting age, gestational age between 23–33
weeks (confirmed by ultrasound before 20 weeks and/or
reliable menstrual dates). Exclusion criteria were high-
order multiple pregnancy greater than twins, ruptured
membranes, major vaginal bleeding, severe pre-eclampsia
or hypertension, fever (body temperature >37.58C), uri-
nary tract infection, fetal/placental abnormalities, serious
maternal disease, any contraindication to the use of beta-
agonists, alcohol or drug abuse, history of hypersensitivity
to any component of the study drugs, previous exposure
to any tocolytic therapy within six hours (or within 12
hours for indomethacin) of study entry, and participation
in a clinical trial of an experimental drug within the previ-
ous month. The inclusion and exclusion criteria in the
remaining three studies differed from the above in minor
details. The study quality characteristics of all identified
trials are presented in a supplementary table [see Addi-
tional file 1 – STable 1].
In Germany, fenoterol is the only betamimetic agent
approved for use in preventing preterm labour [15]. To
the best of our knowledge, and confirmed by our system-
atic search, no clinical trials comparing atosiban directly
with fenoterol exist. Even so, previous analyses of adverse
events reported in trials of atosiban versus three different
betamimetics demonstrated comparable safety profiles of
the latter [18]. Therefore, we did not limit our review of
the evidence to fenoterol, but included all betamimetic
agents, as their efficacy and safety profiles were expected
to be similar. Using the Mantel-Haenszel method (fixed-
effect model), we performed evidence synthesis using a
dedicated statistical package [19].
A cost-minimisation analysis, rather than a cost-effective-
ness analysis, was conducted due to the similar efficacy of
the analysed tocolytic treatments. A review of resource uti-
lisation and expert opinion revealed that costs related to
drug administration were not different and could not be
captured in the German payment system. Diagnostic costs
attributable in cases when the patient was ineligible for
betamimetics (e.g., high cardiovascular risk, diabetes, thy-
rotoxicosis) were not considered, as in such cases alterna-
tive tocolytic treatment is typically preferred in clinical
practice instead of diagnostic testing. Finally, regardless of
the tocolytic agent, we assumed that the costs of monitor-
ing of tocolysis, as well as all other costs related to man-
agement of preterm labour and preterm birth would be
the same in all women experiencing preterm labour. Drug
costs were evaluated at 18 and 48 hours from the time of
hospital admission. For increased accuracy, extended hos-
pitalisation for treatment of emergent adverse events
occurring within the 48 hours period was also factored
into the analysis.
Costing methodology was guided by the German Diagno-
sis Related Group (G-DRG) method of financing of inpa-
tient treatments used in the German health care system.
DRGs are essentially homogeneous average costs groups,
often adjusted for case severity. A certified G-DRG
Grouper [20] was used to calculate cost of treatment of
preterm labour and any associated adverse events of toco-
lysis.
From the payer's (social health insurer's) perspective, all
costs associated with treatment of preterm labour were
encompassed by the flat DRG rate per diagnosed patient.
From this perspective, only extended length of stay and
occurrence of chest pain or dyspnoea had cost conse-
quences resulting from DRG recoding.
From the hospital's perspective, every extension of length
of stay had cost implications for the hospital, even if no
DRG recoding was possible and no additional payments
were due from the payer. DRG tariff was used to obtain
the average cost of a hospitalisation day, based on the
premise that DRG reflects all diagnosis related costs,
including overheads. Since costs of tocolytic drugs were
included in the DRGs, the use of a more expensive drug
generated additional costs for the hospital, whereas the
analysis from the payer's perspective did not involve drug
costs. Costs of atosiban (Tractocile) and fenoterol (Partu-
sisten) were obtained from the hospital purchase price list
[Ferring, data on file] and the Rote Liste [21], respectively.
VAT of 19% was added to the hospital purchase price. We
also calculated the costs from the combined perspective,
theoretical in a system with a payer-provider split, but jus-
tified from the economic point of view. In this approach,
cost of tocolytic drugs, daily cost of extended hospitalisa-
tions, and cost of treatment of adverse events were added.
Details of all cost variables used in the analysis are shown
in Table 1.
The dosing regimen used for the calculation of costs of
drugs was based on the protocols used in the included
clinical trials [22-24]. Atosiban was administered i.v. in aBMC Pregnancy and Childbirth 2009, 9:23 http://www.biomedcentral.com/1471-2393/9/23
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single bolus dose (6.75 mg in 0.9 mL normal saline), with
subsequent infusion of 300 mcg/min atosiban in 5% dex-
trose for the first 3 hours, followed by 100 mcg/min atosi-
ban in 5% dextrose for up to 48 hours. The regimen was
concordant with the recommendation of the German
guidelines for the management of preterm labour [15].
The dosage of fenoterol was adopted from the German
guidelines, with two alternative modalities analysed: con-
tinuous or bolus administrations. In the continuous regi-
men, fenoterol was started at 2 mcg/min, increasing the
dose by 0.8 mcg/min every 20 min; maximum 4 mcg/min.
Bolus tocolysis involved an initial dose of 10 mcg every 3
min with doubling the interval after contractions stopped
(assumed after 1 hour), and further doubling of the inter-
val after 12 and 24 hours. The option of initial increase of
the bolus dosage when tocolysis was not effective was,
conservatively, not considered. Moreover, drug wastage
was accounted for in all scenarios.
The cost-minimisation analyses were conducted using an
economic model developed by the authors in a Microsoft
Excel spreadsheet; the model accounted for the payer-pro-
vider split characteristic of the German system. In the
model, a cohort of 1,000 patients was followed up for up
to 48 hours of hospitalisation for preterm labour. Toco-
lytic treatments were assigned based on the all-patients
treated population from the combined clinical trials. Dis-
continuation of drug administration due to adverse
events, progression of labour, preterm delivery and other
causes was incorporated in the model. Weibull survival
curves were fitted to the data on discontinuation at 48
hours, preterm delivery at 48 hours, and at 7 days. Drug
switching from atosiban to fenoterol or from fenoterol to
another betamimetic was also modelled, based on out-
comes from the clinical trials. Drug switching was
assumed to occur with equal probability during the 48
hours hospitalisation period. Hospitalisation length was
defined based on expert opinion using beta distribution
with the mean of 2.2 days, minimum of 1 day and maxi-
mum of 10 days. Occurrence of adverse events was associ-
ated with risk of extension of the hospitalisation length. It
was assumed that on average only 50% (varied from 20 to
90% in the sensitivity analysis) of the patients experienc-
ing any of the adverse events would require hospitalisa-
tion extended by one or more days. Occurrence of
multiple adverse events was assumed to have the same
consequences as occurrence of any single event. Effec-
tively, we conservatively assumed no consequences of
occurrence of adverse events in 50% of the patients. Sim-
ilarly, diagnosis of chest pain or dyspnoea could lead to
DRG recoding in 50% of the patients, with the same vari-
ation in the sensitivity analysis applied. In the sensitivity
analysis, 95% uncertainty intervals were also estimated
for efficacy, risk of adverse events and unit cost variables.
Results
Based on the three double-blinded, placebo-controlled
trials [22-24], efficacy of atosiban in delaying preterm
birth by at least 48 hours was found to be identical to that
of betamimetics (88.1% versus 88.7%, respectively; RR =
0.99, 95%CI:0.94–1.04, p = 0.772). Addition of a single-
blinded [25] and two open label [26,27] trials resulted in
slightly higher success rates in both treatment groups
(90.2% versus 90.0%, respectively), but also yielded no
significant difference (RR = 1.00, 95%CI:0.97–1.03, p =
0.965).
Meta-analysis of the three double-blinded, placebo-con-
trolled clinical trials revealed, that the use of atosiban was
associated with a significantly lower frequency of adverse
events compared to betamimetics for six out of 16 adverse
events reported. Inclusion of all six studies yielded a sim-
ilar safety profile advantage of atosiban with five out of 16
adverse events occurring with significantly lower fre-
Table 1: Cost variables used as input in the economic model.
Variable Value 95% uncertainty range Reference Comment
Atosiban (Tractocile) 6.5 mg 35.47€ 31.93–39.02€ Ferring, data on file Costs of diagnostics, monitoring and infusion 
fluids considered equal for all treatments; drug 
wastage accounted for; 19% VAT applied.
Atosiban (Tractocile) 37.5 mg 115.29€ 103.76–126.82€ Ferring, data on file Costs of diagnostics, monitoring and infusion 
fluids considered equal for all treatments; drug 
wastage accounted for; 19% VAT applied.
Fenoterol (Partusisten) 0.5 mg 3.75€ 3.37–4.12€ Rote Liste [14] Costs of diagnostics, monitoring and infusion 
fluids considered equal for all treatments; drug 
wastage accounted for; 19% VAT applied.
Preterm labour, one hosp. day 321.90€ Fixed value G-DRG 2007/2008 [13] G-DRG O64B
Preterm labour, more than one 
hosp. day
1,742.90€ Fixed value G-DRG 2007/2008 [13] G-DRG O64A
Chest pain 1,175.50€ Fixed value G-DRG 2007/2008 [13] G-DRG FZ4Z, min. 2 hosp. days were 
assumed for cases with chest pain.
Dyspnoea 2,470.80€ Fixed value G-DRG 2007/2008 [13] G-DRG E64D, min 2 hosp. days were assumed 
for cases with dyspnoea.BMC Pregnancy and Childbirth 2009, 9:23 http://www.biomedcentral.com/1471-2393/9/23
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quency. Disaggregated meta-analysis results for each
adverse event for the three double-blinded trials, as well as
all six included trials are detailed in Tables 2 and 3.
Cost results for the three treatment options based on the
double-blinded clinical trials are presented in Figure 1.
Cost-minimization analysis revealed, that from the
payer's perspective, cost savings from using atosiban ver-
sus fenoterol were 423€ per patient. From the hospital's
perspective, savings from using atosiban versus continu-
ous fenoterol ranged from 259€ for 18 hours of tocolysis
to 105€ for 48 hours, and the respective values for bolus
fenoterol were 244€ and 55€.
From the combined perspective, using atosiban versus
continuous fenoterol saved from 226€ for 18 hours of
tocolysis to 71€ for 48 hours, and versus bolus fenoterol
the results were 211€ and 21€, respectively, jointly for the
payer and hospital.
When all six RCTs were considered, cost savings from the
payer's perspective using atosiban versus fenoterol were
371€ per patient. From the hospital's perspective, savings
from using atosiban versus continuous fenoterol ranged
from 217€ for 18 hours of tocolysis to 62€ for 48 hours,
and the respective values for bolus fenoterol were 202€
and 13€. From the combined perspective, using atosiban
versus continuous fenoterol saved from 210€ for 18 hours
of tocolysis to 56€ for 48 hours, and versus bolus fenote-
rol the results were 195€ and 6€, respectively.
In the probabilistic sensitivity analyses, using data from
the double-blinded trials, cost-savings for the payer varied
in the 1,000 scenarios from 365€ (2.5 percentile) to 473€
(97.5 percentile) per patient. When all six clinical trials
were used in the evidence synthesis, the respective values
were 323€ and 431€. For both the hospital and combined
perspectives, atosiban was cost saving versus both contin-
uous and bolus fenoterol after 18 hours of tocolysis in
100% of scenarios. At 48 hours, atosiban was cost saving
versus continuous fenoterol in 94.4% (89.6% for all six
studies) of cases and versus bolus fenoterol in 87.2%
(83.5% for all six studies) of cases. The respective values
Table 2: Reported adverse events in the double-blinded, placebo-controlled trials only.
Adverse event Frequency (%)
Atosiban
Frequency (%)
Betamimetics
Relative risk and Confidence Intervals p-value
Tachycardia 5.50% 75.50% RR = 0.07,
95% CI = 0.05, 0.11
<0.001
Palpitation 2.20% 15.60% RR = 0.15,
95% CI = 0.07, 0.3
<0.001
Vomiting 6.90% 21.80% RR = 0.31,
95% CI = 0.21, 0.48
<0.001
Headache 9.70% 18.60% RR = 0.52,
95% CI = 0.35, 0.76
<0.001
Hyperglycaemia 6.40% 12.40% RR = 0.53,
95% CI = 0.38, 0.85
0.008
Tremor 1.40% 15.90% RR = 0.09,
95% CI = 0.04, 0.22
<0.001
Nausea 11.90% 15.90% RR = 0.75,
95% CI = 0.52, 1.08
0.121
Dyspnoea 0.30% 7.30% RR = 0.07,
95% CI = 0.02, 0.3
<0.001
Chest pain 1.10% 4.80% RR = 0.22,
95% CI = 0.08, 0.65
0.006
Hypokalemia 0.80% 6.50% RR = 0.15,
95% CI = 0.05, 0.45
<0.001
Hypotension 3.30% 5.70% RR = 0.59,
95% CI = 0.29, 1.16
0.127
Anxiety 1.10% 2.40% RR = 0.46,
95% CI = 0.15, 1.48
0.195
Syncope 0.60% 0.50% RR = 1.02,
95% CI = 0.17, 5.98
0.984
Pulmonary oedema 0.30% 0.50% RR = 0.6,
95% CI = 0.08, 4.45
0.614
Myocardial ischemia 0.00% 0.30% RR = 0.34,
95% CI = 0.01, 8.3
0.509
Foetal tachycardia 3.30% 27.70% RR = 0.13,
95% CI = 0.07, 0.26
<0.001BMC Pregnancy and Childbirth 2009, 9:23 http://www.biomedcentral.com/1471-2393/9/23
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from the combined perspective were 93.0% (91.1% for all
six studies) and 88.2% (85.7% for all six studies).
Discussion
To the best of our knowledge, our study is the first eco-
nomic evaluation of atosiban versus betamimetics based
on evidence of efficacy and safety from a systematic liter-
ature review, and assessing the differential costs of toco-
lysis from the payer's and provider's perspectives.
Heinen-Kammerer et al. [28] previously evaluated atosi-
ban versus fenoterol in the German setting. This study
merits close assessment as its results were later used for
discussion in the context of implications for clinical
practice [29]. Continuous fenoterol alone, continuous
fenoterol with magnesium sulphate and bolus fenoterol
were used as comparators in the decision analytic model.
Success rates in delaying preterm birth by at least 48
hours were chosen as the measure of effectiveness, but
only point estimates of success rates were considered in
the model (0.770 vs. 0.670 vs. 0.626, respectively), with
statistically significant differences implicitly assumed.
The evidence base of the analysis did not appear compre-
hensive, as no study of atosiban versus betamimetics was
considered. For atosiban and bolus fenoterol only one
randomized clinical trial for each option was used as the
source of efficacy data, while for continuous fenoterol
tocolysis, a cohort study from the 1970s was chosen.
Moreover, the study of atosiban had potentially biased
outcomes due to imbalance in randomization with
respect to gestational age. The authors in their model
incorporated only one adverse event, pulmonary
oedema. Our meta-analysis revealed that with regard to
pulmonary oedema the compared options were not sig-
nificantly different. In contrast, for ten other emergent
adverse events the outcomes did differ.
Most importantly, Heinen-Kammerer et al. [28] added to
the calculation the costs of preterm birth and its conse-
quences for up to five years, which favoured fenoterol
over atosiban with no justification in statistical signifi-
cance of differential efficacy. The authors found that con-
tinuous fenoterol was 509€ more expensive than
Table 3: Reported adverse events in all included trials
Adverse event Frequency (%)
Atosiban
Frequency (%)
Betamimetics
Relative risk and Confidence Intervals p-value
Tachycardia 3.90% 56.30% RR = 0.07,
95% CI = 0.05, 0.1
<0.001
Palpitation 2.40% 20.40% RR = 0.12,
95% CI = 0.06, 0.22
<0.001
Vomiting 5.90% 19.20% RR = 0.27,
95% CI = 0.18, 0.4
<0.001
Headache 8.40% 14.10% RR = 0.59,
95% CI = 0.43, 0.8
<0.001
Hyperglycaemia 7.80% 13.30% RR = 0.57,
95% CI = 0.4, 0.89
0.001
Tremor 0.80% 12.20% RR = 0.08,
95% CI = 0.04, 0.19
<0.001
Nausea 8.70% 10.50% RR = 0.79,
95% CI = 0.57, 1.08
0.135
Dyspnoea 0.60% 8.50% RR = 0.09,
95% CI = 0.04, 0.23
<0.001
Chest pain 1.70% 8.00% RR = 0.18,
95% CI = 0.09, 0.38
<0.001
Hypokalemia 0.70% 7.10% RR = 0.13,
95% CI = 0.05, 0.36
<0.001
Hypotension 2.80% 5.00% RR = 0.6,
95% CI = 0.29, 1.11
0.1
Anxiety 1.50% 3.80% RR = 0.43,
95% CI = 0.2, 0.91
0.027
Syncope 0.60% 0.50% RR = 1.02,
95% CI = 0.17, 5.98
0.984
Pulmonary oedema 0.30% 0.50% RR = 0.6,
95% CI = 0.08, 4.45
0.614
Myocardial ischemia 0.00% 0.30% RR = 0.34,
95% CI = 0.01, 8.3
0.509
Foetal tachycardia 2.90% 21.10% RR = 0.14,
95% CI = 0.08, 0.23
<0.001BMC Pregnancy and Childbirth 2009, 9:23 http://www.biomedcentral.com/1471-2393/9/23
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atosiban. Bolus fenoterol, however, was 1,191€ less
expensive in comparison with atosiban; it was also
1,700€ less expensive than continuous fenoterol.
Our analysis of drug costs showed that the continuous
regimen costs only 49€ more than bolus administration
of fenoterol. Due to the markedly higher success rates for
bolus fenoterol than that for continuous fenoterol (77.5%
vs. 62.6%, respectively), assumed by Heinen-Kammerer at
al. [28], most of the cost differential resulted from mater-
nal, neonatal and paediatric treatments, as frequency of
adverse events were assumed identical for the two fenote-
rol regimens. In contrast, with the scope of analysis lim-
ited to the costs of drugs and treatment of adverse events,
adopted in our study, Heinen-Kammerer et al. [28] would
have demonstrated cost savings with atosiban compara-
ble, or greater, than our results not only for continuous,
but also for bolus fenoterol. In the sensitivity analysis, the
authors found that their results were highly dependent on
the values of success rates used as input in the decision
model. Based on this sensitivity, they concluded that no
treatment option could be indicated as the preferred one.
Our model based on input from the statistical analysis of
the best available evidence, demonstrated that superiority
of atosiban was robust in a sensitivity analysis and clear
recommendation for clinical practice in Germany can be
made for the comparison of these two tocolytics.
Both the analysis of Heinen-Kammerer et al. [28] and our
evaluation consider bolus tocolysis with fenoterol as a
valid treatment option. This regimen is used in 20–30% of
German clinics [29]. No clinical trials of bolus fenoterol
versus atosiban have been identified, and results from our
analysis should be viewed considering the assumptions
made with regard to the relative efficacy and safety of con-
tinuous and bolus fenoterol. Differences in efficacy of dif-
ferent tocolytic treatment options was, in turn,
demonstrated between early and standard administration
of atosiban, when pre-defined diagnostic eligibility crite-
ria were met [30]. Inclusion of the immediate treatment
option, which leads to higher success rates (88.9% vs.
76.1%, respectively), in our decision analytic model,
would warrant considering maternal, neonatal and paedi-
atric costs, as in the Heinen-Kammerer et al. [28] model.
Given comparable safety profiles of the two atosiban
arms, we can predict, that early tocolysis with atosiban
would produce even greater cost savings when compared
to betamimetics.
Atosiban was compared to another betamimetic, rito-
drine, in the Spanish setting [31]. The decision-analytic
model was based on the results of a clinical trial of atosi-
ban versus ritodrine [24]. The average cost per patient
treated with atosiban was 364€ greater than with rito-
drine. Atosiban was judged dominated (more expensive
and less effective), but the assumption of higher efficacy
of ritodrine was not grounded in statistical significance.
For the same reason, inclusion of pulmonary oedema
among the adverse events was not warranted, while no
other adverse events were considered in the analysis.
Another economic evaluation of atosiban versus a betami-
metic was conducted in the Czech Republic [32]. This
study was based on the same double-blinded clinical trials
as ours [22-24], and an assumption of the equivalence of
safety profiles of betamimetics used in the studies, of
which none of them are approved for tocolysis in the
Czech Republic, and fenoterol was made. The authors
found, that in the Czech setting, the cost of treatment with
atosiban or fenoterol were comparable at 18 hours, and
atosiban became more expensive for the longer time hori-
zon up to 48 hours. Since the reimbursement system
could be critical in economic analysis (DRG, per diem, per
procedure), applicability of results in different settings can
be limited.
Established for Germany cost savings of 423€ per patient
treated could have significant budget implications for the
payer, if all eligible women are initiated on atosiban
rather than on fenoterol. With the annual number of pre-
term births in Germany greater than 50,000, and based on
the assumption that only half of women who deliver pre-
term are treated with tocolytics, the annual savings could
be in excess of 20 million euros for the payer or 2–12 mil-
lion for the hospitals. The savings would apply even given
that 50–70% of women with symptoms of preterm labour
deliver at term.
It is likely that our simplifying assumptions led to the
underestimation of the cost savings potentially achieved
with atosiban. We considered only direct medical costs
Cost results for the three perspectives for different time  horizons based on evidence from the three double-blinded  clinical trials Figure 1
Cost results for the three perspectives for different 
time horizons based on evidence from the three dou-
ble-blinded clinical trials.
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associated with adverse events. While productivity loss
resulting from extension of hospitalisation length may be
of little importance in the context of consequences of pre-
term labour, direct non-medical costs could be non-triv-
ial. In addition, the disutility resulting from adverse
events was not included in the model.
Exclusion of diagnostic costs was also conservative. In an
economic evaluation of four tocolytics drugs in the US,
costs of cardiac evaluation, electrolyte monitoring and
strict fluid status by means of Foley catheter were included
for the betamimetic arm (terbutaline), because of the risk
of maternal adverse events [17]. Higher incidence of foetal
tachycardia could also lead to increased intensity of cardi-
otocographic monitoring with additional cost implica-
tions. Based on the three high quality studies, there was a
trend for higher risk of caesarean section deliveries in the
betamimetics group than in the atosiban group, but the
difference was not significant at the 95% level (p = 0.059).
In the clinical trials used as the evidence base for the deci-
sion model, patients discontinuing treatment with a beta-
mimetic received an alternative betamimetic agent. In our
model, we assumed no cost consequences of such change,
as no other betamimetic is available for tocolysis in Ger-
many. If such patients were to be administered atosiban
instead, the cost advantage per patient initiated on this
drug would have been greater.
We based our analysis of comparable efficacy and safety
profiles of fenoterol and other betamimetics. No clinical
trial comparing atosiban to fenoterol was identified, but
previously fenoterol showed similar safety profile to rito-
drine for maternal tachycardia and hypoglycaemia [33].
For individual adverse events, ritodrine was, in turn, infe-
rior to terbutaline for hyperglycemia or an abnormal glu-
cose tolerance test and headache, and inferior to
hexoprenaline for palpitations, hypotension, nausea and
vomiting and foetal tachycardia. If the safety profile of
fenoterol is similar to that of ritodrine, and clinical trials
suggest inferiority of ritodrine in comparison to other bet-
amimetics, our approach was conservative, with a possi-
bility of underestimating the risk of adverse events on
fenoterol. Other adverse events reported in trials of beta-
mimetics versus placebo, such as cardiac arrhythmias (not
significant) and nasal stuffiness (significant) [34], which
could potentially occur with fenoterol, were not consid-
ered in the analysis.
Our cost analysis was subordinated to the reimbursement
mechanisms based on the G-DRG tariff, rather than on
detailed analysis of resource utilization and micro-cost-
ing. It was assumed that additional procedures associated
with the treatment of adverse events do not affect the
payer, as one of the reasons for using DRG is to enforce
efficiency by shifting the financial risk to the provider,
who is responsible for resource utilisation. In the longer
term, however, inefficiencies at the provider level, would
affect payer's budget, and detailed analysis of clinical
resource utilisation should be informative for all stake-
holders of the health system.
Results of a comparison of four tocolytics agents in the
United States: nifedipine, magnesium sulphate, terbuta-
line and indomethacin had demonstrated that the latter
two drugs had superior safety profile and were the cheaper
treatment options than the comparators. Interestingly,
these two superior drugs had been shown not to be popu-
lar treatment options in the United States [35], with 69%
of women receiving magnesium sulphate. Similarly, in
the German stetting, we have demonstrated that atosiban
is not only clinically, but also economically superior to
fenoterol, with the latter still being most widely used as
the first line treatment option [28].
Conclusion
In conclusion, in a German setting and according to Ger-
man practice guidelines and treatment costs, atosiban was
shown to be the preferred treatment option owing to cost
savings resulting from its superior safety profile. As treat-
ment safety is one of the clinical priorities, and in light of
the fact that the resources are limited, we envisage that
best available evidence combined with costing studies will
be increasingly considered in making recommendations
and decisions in preterm labour.
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